Skip To Main Content
Bijal Shah on Muck Rack

Bijal Shah

New York
As seen in: Medium, MSN, Nature, The Guardian, Wiley Online Library, Aol, Yahoo Finance, Fortune, Infobae, MDPI and
Author of For the Love of Laxmi

Get in touch with Bijal

Contact Bijal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

America’s layoff safety net was built for a different economy, and AI is about to break it

|
By Bijal Shah
| Human Resource Executive Verified
When an employee loses their job today, they are handed a map to a city that no longer exists. The systems that were meant to catch them—from unemployment insurance and corporate outplacement to federal reemployment programs—were designed for a workforce that cycled through downturns and recovered. Historically, this has looked like cyclical layoffs, concentrated in blue-collar fields, with predictably short unemployment spells. That world is not the one AI-driven displacement is creating.
Open in Who Shared Issue with article?

Bijal Shah

|
By Bijal Shah
| Human Resource Executive Verified
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Click to view our cookie policy
Open in Who Shared View Duplicates (31) Issue with article?

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

|
By Max S. Topp, Bijal Shah, Elias Jabbour, Jae Park, Paul W. Shaughnessy, Aaron Logan, Karamjeet S. Sandhu, Mehrdad Abedi, Michael Bishop, Daniel DeAngelo, Xiang Yin, Ruthanna Davi, Katharine A. Hodby, Ram Malladi, Wolfram Brugger, Claire Roddie, Hagop Kantarjian, Justin Shang
| Nature Verified
Abstract In the single-arm Phase Ib/II FELIX study (NCT04404660), obecabtagene autoleucel (obe-cel; CD19-directed autologous CAR T-cell therapy) demonstrated high overall remission rates (ORR) and a favorable safety profile in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To contextualize results from FELIX, we compared the efficacy and safety of obe-cel with matched external control arms (ECA) derived from historical trials using propensity score matching.
Open in Who Shared Issue with article?
See all 58 licensed articles (135 Total)